Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Poor sleep in patients with multiple sclerosis.
A high-density screen for linkage in multiple sclerosis.
Lipids and lipid-reactive antibodies as biomarkers for multiple sclerosis.
Population Pharmacokinetics of Daclizumab High-Yield Process in Healthy Volunteers and Subjects with Multiple Sclerosis: Analysis of Phase I-III Clinical Trials.
Tip variant focal segmental glomerulosclerosis associated with interferon-β treatment of multiple sclerosis.
A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis.
Autoantibody to MOG suggests two distinct clinical subtypes of NMOSD.
Recombinant T cell receptor ligands: immunomodulatory, neuroprotective and neuroregenerative effects suggest application as therapy for multiple sclerosis.
Tumefactive Multiple Sclerosis presenting as Acute Ischemic Stroke.
Durable pharmacological responses from the peptide drug ShK-186, a specific Kv1.3 channel inhibitor that suppresses T cell mediators of autoimmune disease.
Activation of axonal Kv7 channels in human peripheral nerve by flupirtine but not placebo - therapeutic potential for peripheral neuropathies: results of a randomised controlled trial.
Alemtuzumab use in neuromyelitis optica spectrum disorders: a brief case series.
Effect of Treatment Regimen on the Immunogenicity of Human Interferon Beta in Immune Tolerant Mice.
The epidemiology of multiple sclerosis in Latin America and the Caribbean: a systematic review.
Analysis: Healthy babies born after accelerated elimination of teriflunomide
Novartis gains approval for Gilenya® as a first-line disease modifying oral therapy for multiple sclerosis in Switzerland and Australia
Vitamin D intake and incidence of multiple sclerosis.
Patient reported outcome measures in neurogenic bladder.
Gene expression studies of a human monocyte cell line identify dissimilarities between differently manufactured glatiramoids.
Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome.
IL-21 drives secondary autoimmunity in patients with multiple sclerosis, following therapeutic lymphocyte depletion with alemtuzumab (Campath-1H).
Safety and Efficacy of Fingolimod in Pediatric Patients With Multiple Sclerosis
Apitope Announces Positive Results from Clinical Trial of ATX-MS-1467 in Relapsing Multiple Sclerosis
Corpus callosum atrophy is strongly associated with cognitive impairment in multiple sclerosis: Results of a 17-year longitudinal study.
Dynamic regulatory network controlling TH17 cell differentiation.

Pages